Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Aurinia Pharmaceuticals Inc. keeps $45 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Aurinia Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, with revenue rising 18.9% year over year to about $83.2 million (up from $70.0 million a year ago) while EPS of $0.28 topped the $0.24 estimate, +16.7%. Revenue of $83.2 million also topped the $80.4 million consensus, +3.4%, and profitability stayed high with gross margin near 92% and operating margin around 56%, alongside operating income of roughly $46.3 million. Net income increased 73.9% to about $37.4 million versus $21.5 million a year ago, and the quarter generated operating cash flow of approximately $52.2 million. Next-period consensus calls for EPS of $0.19 on revenue of $83.6 million.
Next report — what to expect
Aurinia Pharmaceuticals Inc. (AUPH) reports earnings on November 3, 2026. Wall Street expects EPS of $0.22 on revenue of $83.6 million; for trailing context, revenue grew +18.9% year over year last quarter. Aurinia has beaten EPS in 6 of 8 most recent quarters, putting focus on delivery versus those consensus levels.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a biotechnology company that develops and commercializes therapies for diseases with inadequate current treatment options. Its business is centered on LUPKYNIS, an approved treatment for active lupus nephritis in adults, and it generated $283.1 million of revenue in FY2025.
Today's Snapshot
AUPH closed 2.7% below yesterday's close, in line with a weaker sector. Earnings are due from AUPH on 3 November.
Trading Volume
Below 10d avg (807.7K)
577.2K
vs S&P 500 Today
Underperforming Market
-2.19%
Updated: October 23, 2026 at 20:13 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$15.71 - $16.73Buy
- RSI (14)56.14Neutral
- Stochastic %K (14, 3, 3)81.89Sell
- MACD Level (12, 26)0.18Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.